These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 7606587

  • 1. Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins.
    Jones RN.
    Am J Health Syst Pharm; 1995 Mar 15; 52(6 Suppl 2):S29-33. PubMed ID: 7606587
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam.
    Nord CE.
    Intensive Care Med; 1994 Jul 15; 20 Suppl 3():S35-8. PubMed ID: 7962987
    [Abstract] [Full Text] [Related]

  • 6. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
    Roland RK, Mendes RE, Silbert S, Bolsoni AP, Sader HS.
    Braz J Infect Dis; 2000 Oct 15; 4(5):226-35. PubMed ID: 11063554
    [Abstract] [Full Text] [Related]

  • 7. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.
    Shlaes DM, Baughman R, Boylen CT, Chan JC, Charan NB, Cormier YC, Erickson A, Grossman R, Kirmani N, Suh B.
    J Antimicrob Chemother; 1994 Oct 15; 34(4):565-77. PubMed ID: 7868408
    [Abstract] [Full Text] [Related]

  • 8. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M, Plosker GL.
    Pharmacoeconomics; 2001 Oct 15; 19(11):1135-75. PubMed ID: 11735679
    [Abstract] [Full Text] [Related]

  • 9. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
    Appelbaum PC.
    J Antimicrob Chemother; 1993 Jan 15; 31 Suppl A():29-38. PubMed ID: 8383654
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD.
    Pharmacotherapy; 2000 Sep 15; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections.
    File TM, Tan JS.
    Eur J Surg Suppl; 1994 Sep 15; (573):51-5. PubMed ID: 7524796
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination.
    Daniel KP, Krop LC.
    Pharmacotherapy; 1996 Sep 15; 16(2):149-62. PubMed ID: 8820460
    [Abstract] [Full Text] [Related]

  • 16. Piperacillin/tazobactam in the treatment of polymicrobial infections.
    Gorbach SL.
    Intensive Care Med; 1994 Jul 15; 20 Suppl 3():S27-34. PubMed ID: 7962986
    [Abstract] [Full Text] [Related]

  • 17. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Bryson HM, Brogden RN.
    Drugs; 1994 Mar 15; 47(3):506-35. PubMed ID: 7514977
    [Abstract] [Full Text] [Related]

  • 18. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
    Birawska I, Fuchs J, Szulakowska E.
    Med Dosw Mikrobiol; 1998 Mar 15; 50(1-2):41-6. PubMed ID: 9857612
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.